Socio-Demographic Profile and Prevalence of Tuberculosis (TB) Treatment Outcomes among Tuberculosis/Human Immunodeficiency Virus (TB/HIV) Co-Infected Patients in Kelantan

被引:0
作者
Nor, Siti Romaino Mohd [1 ,2 ]
Husin, Mohd Rozi [3 ]
Jaeb, Mat Zuki Mat [4 ]
Naing, Nyi Nyi [1 ]
机构
[1] Univ Sultan Zainal Abidin, Fac Med, Med Campus,Jalan Sultan Mahmud, Kuala Terengganu 20400, Terengganu, Malaysia
[2] Hosp Raja Perempuan Zainab II, Clin Res Ctr Kelantan, Kota Baharu 15586, Kelantan, Malaysia
[3] Jabatan Kesihatan Negeri Kelantan, TB Leprosy Sect, Kota Baharu 15200, Kelantan, Malaysia
[4] Hosp Raja Perempuan Zainab II, Dept Med, Resp Unit, Kota Baharu 15586, Kelantan, Malaysia
来源
PERTANIKA JOURNAL OF SCIENCE AND TECHNOLOGY | 2021年 / 29卷 / 04期
关键词
Co-infected patients; Human Immunodeficiency Virus; HIV; prevalence; socio-demographic; Tuberculosis; TB; PREDICTORS;
D O I
10.47836/pjst.29.4.03
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
In Kelantan, the prevalence of Tuberculosis (TB) treatment success rate among TB/HIV co-infection is still below the success target of the World Health Organisation (WHO). Our objective was to assess the socio-demographic profile and determine the prevalence of TB treatment outcomes among TB/HIV co-infected patients in Kelantan. The crosssectional study involved secondary data from the MyTB online system from January 2014 to December 2018, carried out at TB/Leprosy Sector, State Health Department of Kelantan. The data were analysed using SPSS version 25.0 and STATA version 14. The ethics approval was obtained from the UniSZA Human Research Ethics Committee (UHREC) and Medical Research Ethics Committee (MREC) of Ministry of Health (MOH). There were 6,313 TB cases in Kelantan. Of these, 703 (11.1%) cases were TB/HIV co-infection. However, 36 cases were excluded, and 667 cases were evaluated based on inclusion and exclusion criteria. The mean (SD) age was 38.7 (7.9) years, and the mean duration of TB treatment was 202.8 (131.27) days. The prevalence of successful treatment was 57.1%, with 19.8% cases were cured, and another 37.3% cases were completed treatment. While the unsuccessful were 42.9%, with 10.1% cases were defaulted, and 32.8% cases died. The successful outcomes were significantly associated with the educational level, the anatomy of TB location, smoking status, DOTS by health care providers, source of notification, the place of treatment and method of detection. This study provides the basic data of patient's socio-demographic profiles, and the prevalence of TB treatment success in Kelantan is under international target by WHO of >= 90.0%.
引用
收藏
页码:2279 / 2293
页数:15
相关论文
共 50 条
  • [31] Treatment outcome and mortality: Their predictors among HIV/TB co-infected patients from Iran
    Tabarsi, Payam
    Chitsaz, Ehsan
    Moradi, Ahmadreza
    Baghaei, Parvaneh
    Marjani, Majid
    Mansouri, Davood
    INTERNATIONAL JOURNAL OF MYCOBACTERIOLOGY, 2012, 1 (02) : 82 - 86
  • [32] Differential Epigenetic Regulation in Uninfected and Tuberculosis-Human Immunodeficiency Virus Co-Infected Patients
    Mamabolo, Katlego
    Wadee, Reubina
    Perner, Yvonne
    Magangane, Pumza
    Duze, Sanelisiwe Thinasonke
    Marimani, Musa
    MICROORGANISMS, 2024, 12 (05)
  • [33] Converging Epidemics: A Narrative Review of Tuberculosis (TB) and Human Immunodeficiency Virus (HIV) Coinfection
    Bhatt, Asmi
    Syed, Zahiruddin Quazi
    Singh, Harshit
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (10)
  • [34] Association between TB delay and TB treatment outcomes in HIV-TB co-infected patients: a study based on the multilevel propensity score method
    Liao, Rujun
    Hu, Lin
    Yu, Jie
    Chen, Ying
    Chen, Miaoshuang
    Yan, Jingmin
    Li, Xin
    Han, Xinyue
    Jike, Chunnong
    Yu, Gang
    Wang, Ju
    Liao, Qiang
    Xia, Lan
    Bai, Xuefei
    Shi, Jinhong
    Jiang, Tian
    Du, Liang
    Zhang, Tao
    BMC INFECTIOUS DISEASES, 2024, 24 (01)
  • [35] Infection of multiple Mycobacterium tuberculosis strains among tuberculosis/human immunodeficiency virus co-infected patients: A molecular study in Myanmar
    Kyi, Myo Su
    Palittapongarnpim, Prasit
    Chaiprasert, Angkana
    Ajawatanawong, Pravech
    Garcia, Hector Guzman
    Chongsuvivatwong, Virasakdi
    INTERNATIONAL JOURNAL OF MYCOBACTERIOLOGY, 2018, 7 (04) : 375 - 379
  • [36] Delays in HIV and TB diagnosis and treatment initiation in co-infected patients in Colombia
    Yaneth Rios-Hincapie, Cielo
    Rojas, Marcela
    Lopez, Martha
    Porras, Alexandra
    Luque, Ricardo
    Pelissari, Daniele Maria
    Lopez, Lucelly
    Vanessa Rueda, Zulma
    INTERNATIONAL JOURNAL OF STD & AIDS, 2020, 31 (05) : 410 - 419
  • [37] Prognostic score to predict mortality during TB treatment in TB/HIV co-infected patients
    Nguyen, Duc T.
    Jenkins, Helen E.
    Graviss, Edward A.
    PLOS ONE, 2018, 13 (04):
  • [38] Virologic and immunologic outcome of HAART in Human Immunodeficiency Virus (HIV)-1 infected patients with and without tuberculosis (TB) and latent TB infection (LTBI) in Addis Ababa, Ethiopia
    Desta Kassa
    Gebremedhin Gebremichael
    Yodit Alemayehu
    Dawit Wolday
    Tsehaynesh Messele
    Debbie van Baarle
    AIDS Research and Therapy, 10
  • [39] Survival Rate and Predictors of Mortality Among TB-HIV Co-Infected Patients During Tuberculosis Treatment at Public Health Facilities in Bahir Dar City, Northwest Ethiopia
    Kegne, Teshager Worku
    Anteneh, Zelalem Alamrew
    Bayeh, Tadios Lidetu
    Shiferaw, Birhanu Melaku
    Tamiru, Desiyalew Habtamu
    INFECTION AND DRUG RESISTANCE, 2024, 17 : 1385 - 1395
  • [40] Association between antiretroviral therapy and antitubercular drug resistance in TB treatment outcome among Kazakh TB/HIV co-infected patients
    Mishkin, Kathryn
    Alaei, Kamiar
    Alikeyeva, Elmira
    Paynter, Christopher
    Aringazina, Altyn
    Alaei, Arash
    JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2018, 14 : 104 - 108